Merck announces updated late-stage pipeline following its recent merger with Schering-Plough

February 29, 2016

"Since the announcement of the merger in March 2009, we have received regulatory approvals for SIMPONI?�? (golimumab), SAPHRIS?� (asenapine) and ELONVA?�, (corifollitropin alfa injection). In addition, following the closing of the merger, we have made important progress in defining our new pipeline and advancing new projects," said Dr Kim. "Merck is poised to continue to build on our current portfolio and deliver even more on our commitment to improve human health."

The complementary nature of the two pipelines is underscored by the fact that only two programs, hepatitis C and cancer, needed to prioritize a lead molecule for continued development. Vaniprevir (MK-7009), a second-generation hepatitis C protease inhibitor candidate and dalotuzumab (MK-0646), an IGF-1R inhibitor, both currently in Phase II clinical trials, were selected to continue development.

Notable recent pipeline progress includes the initiation of Phase III trials for MK-4305, the company's novel orexin antagonist being evaluated for insomnia, and an allergy immunotherapy tablet for ragweed allergies (SCH 39641). In addition, a Phase II study evaluating MK-6913 for the treatment of hot flashes in postmenopausal women has been initiated.

The new pipeline lists investigational candidates in Phase II and Phase III of clinical development as well as four compounds currently under regulatory review. In addition, marketing rights in specific geographic regions are detailed.

SOURCE Merck & Co., Inc.